author-photo

Anu Sikiö

19

Papers

83

Citations

Citation Trend

Filter By

Papers (16) Sort By

Journal Conference Others

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

2020 Blood
Show All
- Source
- Cite
- Save
Citations (1)
CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non‐Hodgkinʼs lymphoma patients: results of the prospective multicenter Goa study

2020 Transfusion
Show All
- Source
- Cite
- Save
Citations (3)
Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients

2020 Blood
Show All
- Source
- Cite
- Save
Citations (1)
A phase 2 study of carfilzomib plus elotuzumab plus dexamethasone for myeloma patients relapsed after 1-3 prior treatment lines

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (2)
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group

2019 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (5)
A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines

2018 Blood
Show All
- Source
- Cite
- Save
Citations (1)
A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.

2016 Bone Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (30)
RVD + ASCT + Lenalidomide Maintenance Benefits Patients without High-Risk Cytogenetics and Results in Recovery of the Normal Plasma Cell Composition in Bone Marrow

2016 Blood
Show All
- Source
- Cite
- Save
Citations (4)
A randomized phase II study of stem cell mobilization with cyclophosphamide + G-CSF versus G-CSF alone after lenalidomide-based induction in multiple myeloma

2015 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
A Prospective Phase 2 Study to Assess Immunophenotypic Remission after Lenalidomide-Based Induction Followed By ASCT and Lenalidomide Maintenance in Patients with Newly Diagnosed Multiple Myeloma

2015 Blood
Show All
- Source
- Cite
- Save
Citations (0)